GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Cash Flow from Investing

Asensus Surgical (Asensus Surgical) Cash Flow from Investing : $37.77 Mil (TTM As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Asensus Surgical spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $3.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Asensus Surgical gained $3.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Asensus Surgical Cash Flow from Investing Historical Data

The historical data trend for Asensus Surgical's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Cash Flow from Investing Chart

Asensus Surgical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.65 - -119.67 47.54 64.51

Asensus Surgical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.74 6.56 20.78 7.43 3.00

Asensus Surgical Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Asensus Surgical's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Asensus Surgical's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asensus Surgical  (AMEX:ASXC) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Asensus Surgical's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Asensus Surgical's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Asensus Surgical's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Asensus Surgical's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Asensus Surgical's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Asensus Surgical's sale of investment for the three months ended in Mar. 2024 was $3.00 Mil. It means Asensus Surgical gained $3.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Asensus Surgical's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Asensus Surgical's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Asensus Surgical paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Asensus Surgical's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Asensus Surgical paid $0.00 Mil for other investing activities.


Asensus Surgical Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Asensus Surgical (Asensus Surgical) Business Description

Traded in Other Exchanges
Address
1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Executives
Starling William N Jr director 2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi director C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert director 343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J. officer: Chief Technology Officer 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze officer: EVP, Chief Financial Officer C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh officer: Interim CFO 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery officer: EVP and CFO C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith officer: Chief Commercial Officer 7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope director, officer: President and CEO C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a 10 percent owner VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Asensus Surgical (Asensus Surgical) Headlines

From GuruFocus

TransEnterix and Butterfly Among Medtech M&A Opportunities

By Barry Cohen Barry Cohen 12-23-2020